PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
Authors
Keywords
Ovarian cancer, PI3K, AKT, mTOR
Journal
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
Volume 290, Issue 6, Pages 1067-1078
Publisher
Springer Nature
Online
2014-08-02
DOI
10.1007/s00404-014-3377-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients withPIK3CAmutant advanced solid tumors: preliminary efficacy and safety in patients withPIK3CAmutant ER-positive (ER+) metastatic breast cancer (MBC)
- (2014) D Juric et al. CANCER RESEARCH
- Targeting EGFR and PI3K pathways in ovarian cancer
- (2013) S Glaysher et al. BRITISH JOURNAL OF CANCER
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- Epidemiology of Malignant Cervical, Corpus Uteri and Ovarian Tumours - Current Data and Epidemiological Trends
- (2013) A. Waldmann et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- mTOR is a key modulator of ageing and age-related disease
- (2013) Simon C. Johnson et al. NATURE
- New insights into ovarian cancer pathology
- (2012) J. Prat ANNALS OF ONCOLOGY
- PTENgenomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity
- (2012) Khalil Choucair et al. BMC CANCER
- Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
- (2012) D H Yoon et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
- (2012) Gordana Vlahovic et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Role of the inositol polyphosphate-4-phosphatase type II Inpp4b in the generation of ovarian teratomas
- (2012) Ashwini Balakrishnan et al. DEVELOPMENTAL BIOLOGY
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
- (2012) D. Mahadevan et al. EUROPEAN JOURNAL OF CANCER
- Targeting the PI3K signaling pathway in cancer therapy
- (2012) Chandra Bartholomeusz et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells
- (2012) Xin Fu et al. FEBS LETTERS
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
- (2012) Siqing Fu et al. GYNECOLOGIC ONCOLOGY
- Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies
- (2012) Celeste Leigh Pearce et al. LANCET ONCOLOGY
- Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
- (2011) C. Santiskulvong et al. CLINICAL CANCER RESEARCH
- Current and future directions in mammalian target of rapamycin inhibitors development
- (2011) Angelica Fasolo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
- (2011) Kian Behbakht et al. GYNECOLOGIC ONCOLOGY
- Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
- (2011) Robert J. Kurman et al. HUMAN PATHOLOGY
- Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells
- (2011) Tiera A. Liby et al. INTERNATIONAL JOURNAL OF CANCER
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
- (2011) K. M. Kinross et al. MOLECULAR CANCER THERAPEUTICS
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
- (2011) Yesid Alvarado et al. Targeted Oncology
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Genomic Complexity and AKT Dependence in Serous Ovarian Cancer
- (2011) Aphrothiti J. Hanrahan et al. Cancer Discovery
- PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients
- (2010) Iwona K. Kolasa et al. CANCER BIOLOGY & THERAPY
- Regulation of autophagy by phosphatidylinositol 3-phosphate
- (2010) Chloe Burman et al. FEBS LETTERS
- A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies
- (2010) Sarah M. Temkin et al. GYNECOLOGIC ONCOLOGY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains
- (2010) B. Miao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
- (2009) Kuan-Ting Kuo et al. AMERICAN JOURNAL OF PATHOLOGY
- Status of PI3K inhibition and biomarker development in cancer therapeutics
- (2009) B. Markman et al. ANNALS OF ONCOLOGY
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
- (2009) Christina Gewinner et al. CANCER CELL
- Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers
- (2009) Yoo-Kyung Lee et al. GYNECOLOGIC ONCOLOGY
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The regulation and function of Class III PI3Ks: novel roles for Vps34
- (2008) Jonathan M. Backer BIOCHEMICAL JOURNAL
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
- (2008) J. R. Garlich et al. CANCER RESEARCH
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
- (2008) Mariona Graupera et al. NATURE
- Targeting phosphoinositide 3-kinase—Moving towards therapy
- (2007) Romina Marone et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started